There were 1,685 press releases posted in the last 24 hours and 426,846 in the last 365 days.

Global Sample Preparation for Next Generation Sequencing (NGS) Market 2015-2020

Dublin, May 30, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "The Market for Sample Preparation for Next Generation Sequencing (NGS)" report to their offering.

The Market for Sample Preparation for Next Generation Sequencing (NGS)

The Market for Sample Preparation for Next Generation Sequencing (NGS) focuses on the market for NGS sample preparation products, which includes the hardware and consumables.

The threats of disruptive technologies and regulatory constraints are ever-present factors, which are covered in detail. The report discusses some of the key challenges in the market for library preparation and target enrichment products, and provides some strategic recommendations that can be used to address the situations.

It discusses trends, challenges, strategies, companies, and products, and provides estimates of market share and revenue growth for the market, including:

  • NGS Sample Preparation Revenues and Growth Rate, 2015-2020
  • Revenues by Region, 2015 (N. America, Europe, Asia-Pacific, Rest-of-World)
  • Revenues by Product Type, 2015 (Enrichment, libr prep kits panels, etc.; Automation/ hardware; Nucleic acid extraction; Total)
  • NGS Sample Preparation Leading Company Revenues and Market Shares, 2015

The report highlights some of the major trends taking place in the market for library preparation and target enrichment for NGS. There are some areas of rapid change, but also many things that are staying relatively consistent.

  • Some of the trends examined include:
  • Significant Efforts in Automation, Miniaturization
  • Rapid Adoption of Smaller Sequencers Driving Applications
  • Expanding Clinical Adoption Sustains High Growth

The Market for Sample Preparation for NGS provides profiles of the leading companies in the NGS sample preparation and library preparation market, including:

  • Agilent Technologies
  • F. Hoffmann-La Roche AG
  • Illumina
  • Thermo Fisher Scientific

Key Topics Covered:


  • Introduction
  • Product Introductions, Indications of Price Pressure
  • Stability in Sequencers Appears to Be Continuing
  • A Period of Rapid Adoption, But Lower Prices
  • High Likelihood of Longer-Term Challenges
  • Growth -- But Competitive, Concentrated, and Unpredictable
  • Background
  • Scope and Methodology
  • Applications and Definitions


  • Significant Efforts in Automation, Miniaturization
  • Mergers, Acquisitions, Equity Investments Increasing
  • Rapid Adoption of Smaller Sequencers Driving Applications
  • Expected Sequencer Platforms Stalled or Cancelled
  • Stability Despite Possibility of Disruptive Technologies
  • Sequencer Unit Sales Continue Momentum
  • Expanding Clinical Adoption Sustains High Growth
  • China Becoming Major Player in Market
  • Distribution Deals Increase as Smaller Companies Enter Market
  • Regulatory Situation Unclear But Evolving Somewhat


  • Recent Product Introductions


  • Revenues Forecast
  • Revenues by Region
  • Revenues by Product Type
  • Illumina Consumables Revenues


  • Introduction
  • Relative Stability in Sequencer Platforms
  • NGS Sample Preparation Market Shares
  • Smaller Companies Experiencing Mixed Success


  • Sequenom, Several NIPT Companies Fighting
  • Ariosa Diagnostics (Roche) Files Suit against Sequenom
  • Natera Sues Sequenom; Sequenom Sues Natera
  • Verinata Health and Stanford File Against Sequenom
  • Verinata Health Against Ariosa and LabCorp
  • Illumina Sues Ariosa Diagnostics For NIPT Test
  • Illumina Sues Premaitha Health for NIPT Test
  • Illumina Sues Premaitha and Ariosa Partners
  • Sequenom and Illumina Settle and Pool Patents
  • Sequenom Petitions Supreme Court
  • Illumina's Conflicts With Oxford Nanopore
  • Enzo Biochem Brings Suit against Numerous Companies
  • 454 (Roche) Sues Ion Torrent (Thermo Fisher)
  • RainDance Technologies Sues 10X Genomics
  • 10X Genomics' Dispute with Bio-Rad
  • Sequenom Shareholder Sues Over Price Capping
  • Class Action Shareholder Lawsuit Filed Against Pacific Biosciences
  • Helicos' Patent Infringement Suit against PacBio, Life Technologies, and Illumina
  • Illumina's Two Lawsuits against Complete Genomics for Infringement
  • Life Technologies and Illumina Dispute Over Amplification on Solid Surfaces
  • Life Technologies Files Infringement Suit against Promega
  • Enzo Biochem Disputes Sequencing Patents
  • Azco Biotech Sues Qiagen and Intelligent Bio-Systems
  • Intelligent Bio-Systems (Qiagen) and Columbia University Sue Illumina for
  • Infringement
  • LabCorp's Esoterix Sues Life Technologies
  • Genetic Technologies Sues Several Firms for Infringement of Haplotype
  • Determination Technique
  • Illumina Sues Life Technologies Over Ion Torrent Systems
  • Affymetrix Dismisses Suit against Pacific Biosciences and Former Employees
  • Life Technologies Defeats VisiGen Stakeholders after Arbitration
  • Catalyst Assets Sues Life Technologies for Infringement
  • Patent Interference between Life Technologies and Pacific Biosciences
  • LadaTech Sues Illumina Over DNA Amplification Patent
  • Illumina Files 841 Patent Infringement Suit against Affymetrix
  • Affymetrix and Illumina Settle Case Over 243, 432, 531, 365, and 716
  • Applied Biosystems and Illumina Claims and Counter-Claims Over Sequencingby-
  • Ligation Both Unsuccessful



  • 10X Genomics
  • Agilent Technologies
  • F. Hoffmann-La Roche AG
  • Fluidigm
  • Illumina
  • New England Biolabs
  • Oxford Nanopore
  • Pacific Biosciences
  • Qiagen
  • Thermo Fisher Scientific


  • Challenges
  • Unknown Effects of Closed Systems, Automation, Streamlining
  • Medical/ Scientific Discoveries Can Reduce Markets
  • Highly Concentrated Sequencer Market Increases Risks
  • Dropping Sequencing Costs Create Complex Situations
  • Sample Preparation Customer Loyalty Lacking
  • Shortcomings and Pitfalls Require Solutions
  • Low Barriers Cause Increased Competition Short-Term
  • Uncertainty and Debate with LDT Regulation and Adoption
  • Complexity and Difficulty Restrains Broad Adoption
  • Many Labs Opting for Services over Purchasing Sequencers
  • Strategic Recommendations
  • Expanding Market Requires Technical Support
  • Reduce Bias, Compensate, or Characterize It
  • Capitalize on Stability While Preparing for Contingencies
  • Address or Anticipate Price Pressure
  • Benefit from Partnering or Communicating
  • Complementary Products, Other Ways to Hedge
  • Use Services for Visibility and Monetization
  • Address or Ease Data Analysis Challenges
  • Anticipate or Position for Global Adoption

For more information visit

CONTACT: Research and Markets
         Laura Wood, Senior Manager

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Molecular Diagnostics 

Primary Logo